Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Matcha, a powdered form of green tea, has garnered attention for its potential to mitigate some side effects of chemotherapy, primarily due to its high content of catechins, especially epigallocatechin gallate (EGCG). Scientific studies have explored green tea’s antioxidant and anti-inflammatory properties, which could theoretically help reduce oxidative stress and tissue damage induced by chemotherapy. Preliminary research, including in vitro and animal studies, suggests that green tea catechins may help protect healthy cells from damage, support immune function, and possibly alleviate fatigue and nausea—common chemotherapy side effects.

However, clinical evidence in humans specifically regarding matcha and chemotherapy side effects remains limited. Small-scale human studies and anecdotal reports hint at benefits such as improved quality of life and reduced severity of mucositis (oral inflammation) and nausea, but these findings are not yet robust or consistent across studies. Additionally, some research warns of potential interactions between green tea components and certain chemotherapy drugs, which could theoretically reduce treatment efficacy.

In summary, while there is some scientific rationale and preliminary evidence to support the use of matcha (or green tea) to reduce chemotherapy side effects, the evidence is not strong enough for routine recommendation without medical supervision. Patients should always consult their oncologist before incorporating matcha or green tea supplements during chemotherapy.

More about Matcha
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Matcha

Products containing Matcha